ACST News and Press, Acasti Pharma Inc. From 02/23/20

Amarin Looks Promising Ahead of Full Year Results, Receives Upgrade Amarin ( AMRN ) received a boost when Citigroup upgraded its stock to Buy. The target price for the stock has been set at $24 a share, showing considerable upside from the current market price, but still below its recent h...

Acasti Pharma Inc. (ACST) Q3 2020 Results Conference Call February 14, 2020 01:00 PM ET Company Participants David Waldman - IR Jan D’Alvise - President and CEO Pierre Lemieux - COO, Chief Scientific Officer and Co-Founder Brian Groch - Chief Commercial Officer Jean-Fr...

LAVAL, Québec, Feb. 14, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre &#x...

LAVAL, Quebec, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre&...

Investigation underway into unexpected and inconsistent findings that may have negatively impacted results reported in TRILOGY 1 Announces plans to seek FDA guidance prior to unblinding TRILOGY 2 data, which is expected to delay reporting of TRILOGY 2 topline results until calendar Q3...

Penny Stocks To Watch After News If there’s one thing that can trigger a rally in penny stocks , it’s news. Whether it comes from a major industry leader or the company itself, penny stock news can become a big factor in breakouts or break downs. In fact, many times you’...

Amarin Corporation PLC ( AMRN ) is currently on a roll as the company is gearing up for the expanded market launch of its potential blockbuster drug Vascepa, which is now the only drug approved in the United States for lowering the risk of cardiovascular events in conjunction with statin the...

After a failed drug study and massive drop in value for Acasti Pharma (NASDAQ: ACST ,TSXV:ACST),  Neptune Wellness Solutions (NASDAQ: NEPT ,TSX:NEPT) has revealed it recently sold over 1.9 million shares of the company. On Monday (January 13), Neptune informed investors of the months...

A flurry of events have hit the omega-3 landscape on January 13. Long story short, it looks like Amarin ( AMRN ) will be able to rapidly dominate the prescription omega-3 market over the course of 2020 and for the foreseeable future. Quick intro to omega-3s As a quick reminder, the main ma...

Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP )  +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...